Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis, Pfizer Advance Their NASH Ambitions Separately, As Partners

Nov 14 2019

• By Joseph Haas

Liver Meeting Update, Boston 2019 — Pfizer, Novartis are working to launching a Phase II NASH combo study in 2020

Related Content

Intercept Says Data Indicate Pruritus Worries In NASH Could Be Overstated

Nov 11 2019

Novartis Adds To NASH Pipeline By Licensing Pliant’s Integrin Inhibitor

Oct 23 2019

Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development

Oct 29 2018

Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds

Apr 30 2018

Conatus Accepts Defeat For Emricasan In NASH

Jun 25 2019

Related Companies

Novartis AG

Pfizer Inc.

Intercept Pharmaceuticals, Inc.

Gilead Sciences, Inc.

IFM Tre

Pliant Therapeutics, Inc.

Allergan plc

Conatus Pharmaceuticals Inc.

Additional Topics

Business Strategies Deals Commercial Liver & Hepatic BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window